NMRD

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

Retrieved on: 
Thursday, September 14, 2023
National Health Service, Calendar, Nemaura Medical, SFDA, Panel, Hearing, Staff, NMRD, UK, Food, Pharmaceutical industry

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points: 
  • LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
  • (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market.
  • The Company plans to timely request such hearing and is considering all options available to it to regain compliance and maintain its listing on The Nasdaq Capital Market.
  • Dr Faz Chowdhury, the Company’s Chief Executive Officer, commented, “We are hopeful that there will be a positive outcome from a hearing before the Panel.

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

Retrieved on: 
Wednesday, September 13, 2023
CGM, Weight, Exercise, Male, Diet, Cael Sanderson, Weight loss, Mind, BMI, Health, NMRD, Empowerment, Female, Medical device, Birth control, Online shopping

(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program.

Key Points: 
  • (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program.
  • The multi-centered study was run in collaboration with the UK’s National Health Service.
  • None of those invited to participate had expressed a willingness to join a metabolic weight loss program or had previously heard of the Miboko program.
  • Participants used the Miboko app, and were given access to relevant education modules relating to aspects of metabolic health and weight loss.

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

Retrieved on: 
Tuesday, September 12, 2023
CGM, Diabetes, Continuous glucose monitor, Prediabetes, Patient, Korea Disease Control and Prevention Agency, Architecture, Health, Nemaura Medical, NMRD, Dietary supplement, Medical device

LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points: 
  • LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
  • (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October.
  • To support third parties, the Company has made modifications to its architecture to enable sensor integration with other digital programs.
  • This strategy is expected to allow Nemaura to scale its commercialisation programs rapidly and cost-efficiently.

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Retrieved on: 
Monday, September 11, 2023
CGM, CE, Male, Type 2 diabetes, Diabetes, Nemaura Medical, Saudi Food and Drug Authority, SFDA, Person, MARD, Patient, Ageing, NMRD, Skin, Female, Calibration

The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.

Key Points: 
  • The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.
  • This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin.
  • The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear.
  • The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.

Nemaura Medical Announces SFDA Approval of sugarBEAT®

Retrieved on: 
Thursday, August 17, 2023
Obesity, Type 2 diabetes, Prevalence, Diabetes, Nemaura Medical, Economist, Saudi Food and Drug Authority, SFDA, Government, Economist Intelligence Unit, Risk, NMRD, News, Pharmaceutical industry

Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT®, its non-invasive wearable glucose sensor.

Key Points: 
  • Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT®, its non-invasive wearable glucose sensor.
  • The report states that nearly 4.5 million people, or 18.3% of the adult population in Saudi Arabia, have diabetes, compared to a global average of 9.3%.
  • Nemaura Medical is in advanced discussions to play a pivotal role in the region with its superior sensor technology, and diabetes and metabolic health management programs.
  • The Company believes that SFDA approval places Nemaura Medical in an unparalleled position to gain approval across the Gulf and other regions, and to commercialise its digital programs.

Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Benchmark, Weight loss, Benchmark Electronics, NHS, Research, FDA, NMRD, National Health Service, CMO, Aircraft, Nemaura Medical, Pharmaceutical industry, Cryptocurrency

Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended June 30, 2023 and provided a business update.
  • Previously announced initial patient data from UK NHS (National Health Service) Miboko Study that thus far demonstrated weight loss in 100% of participants.
  • Continued development of its consumer metabolic health platform and potential deployment as a bolt-on service into existing metabolic and wellness programs.
  • Research and development (“R&D”) expenses were $549,012 and $330,055 for the three months ended June 30, 2023 and 2022, respectively.

Nemaura Medical Secures $6.5m in Non-Dilutive Funding

Retrieved on: 
Friday, August 11, 2023
NHS, Obesity, American Diabetes Association, Nemaura Medical, Prediabetes, NMRD, National Health Service, Security (finance), Pharmaceutical industry

Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender.

Key Points: 
  • Loughborough, England, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender.
  • In July 2023 Nemaura exhibited and undertook product demonstrations at the American Diabetes Association meeting in San Diego, the world’s largest gathering of Diabetes professionals, where it received very encouraging feedback from dialogue with attendees including corporates, Diabetes service providers and clinicians, which it continues to follow up on.
  • The company is also currently undertaking studies with the NHS (National Health Service) in the UK with its metabolic health program designed for the consumer market targeting obesity and pre-diabetes whilst refining its commercial offering in this space.
  • Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT® in the UK.

Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023

Retrieved on: 
Friday, July 14, 2023
Benchmark, Insurance, Advertising, National Health Service, Feedback, Weight loss, KSA, CMO, Metabolism, MSW, Benchmark Electronics, NHS, Research, FDA, NMRD, Diabetes, Pharmaceutical industry, Nemaura Medical

Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023.

Key Points: 
  • Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and financial results for the fiscal year ended March 31, 2023.
  • Signed a preliminary agreement with Eversana to support a planned commercial launch of its Diabetes and Metabolic Health programs in the USA.
  • Announced initial patient data from UK NHS (National Health Service) Miboko Study that thus far demonstrated weight loss in 100% of participants, with further studies ongoing.
  • General and administrative expenses were $6,590,227 and $6,173,049 for the fiscal years ended March 31, 2023 and 2022, respectively.

Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023

Retrieved on: 
Tuesday, June 27, 2023
Pressure, Kidney failure, Diabetes, Amputation, Stroke, Calendar, Cancer, Paratriathlon, Aircraft, CDC, Blood, Nigeria Centre for Disease Control, AI, Health, NMRD, Medical device, Nemaura Medical

The pilots are intended as a precursor to revenue generating contracts for proBEAT™ and will commence over the coming weeks and months.

Key Points: 
  • The pilots are intended as a precursor to revenue generating contracts for proBEAT™ and will commence over the coming weeks and months.
  • The Company is continuing its discussions with corporations and health insurers in the U.S. to further increase the number of pilots that will run in calendar year 2023.
  • The Centre for Disease Control (CDC) estimate that 37.3 million people have diabetes in the United States (11.3% of the US population).
  • Sensors that can provide feedback on health and wellness enhance both health outcomes and returns on investment for program providers and payers.

Nemaura Medical to Participate at the Collision Conference in Toronto June 26-29, 2023

Retrieved on: 
Thursday, June 22, 2023
Type 2 diabetes, Nemaura Medical, Type 2, Enercare Centre, AI, Prediabetes, NMRD, Conference, Rare-earth element, Medical device

LOUGHBOROUGH, June 22, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces that it will be participating at the upcoming Collision Conference being held at the Enercare Centre in Toronto, Canada on June 26-29, 2023.

Key Points: 
  • LOUGHBOROUGH, June 22, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces that it will be participating at the upcoming Collision Conference being held at the Enercare Centre in Toronto, Canada on June 26-29, 2023.
  • The Collision Conference brings together leading technology companies and an expected 40,000 attendees and top media representatives.
  • Nemaura will present live demonstrations of its wearable daily non-invasive glucose sensor and host 1x1 meetings with investors and media.
  • The company has developed an AI driven analytics platform for both Type 2 diabetes prevention and Type 2 diabetes management.